m3taversal
76e81ea220
- What: first divergence instances — AI labor displacement (cross-domain), GLP-1 economics (health), prevention-first cost dynamics (health), futarchy adoption (internet-finance), human-AI clinical collaboration (health) - Why: divergences are the game mechanic — no instances means no game. All 5 surfaced from genuine competing claims with real evidence on both sides. - Connections: each divergence includes "What Would Resolve This" research agenda as contributor hook Pentagon-Agent: Leo <A3DC172B-F0A4-4408-9E3B-CF842616AAE1>
4.3 KiB
| type | title | domain | description | status | claims | surfaced_by | created | ||
|---|---|---|---|---|---|---|---|---|---|
| divergence | Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence? | health | These are opposite cost problems from the same drug class — one assumes lifelong use drives inflation, the other shows 85% discontinuation undermines the chronic model. The answer determines payer strategy, formulary design, and the health domain's cost trajectory claims. | open |
|
leo | 2026-03-19 |
Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
The KB holds two claims about GLP-1 economics that predict opposite problems from the same drug class. Both are backed by large datasets. Both are rated likely. They can't both be right about the dominant cost dynamic.
The inflationary claim assumes chronic use at $2,940+/year per patient creates unsustainable cost growth through 2035. The model depends on patients staying on treatment indefinitely — the "chronic use model" in the title.
The persistence claim shows that assumption doesn't hold: real-world data from 125,000+ commercially insured patients shows 85% discontinue by two years for non-diabetic obesity. If most patients don't sustain use, the chronic cost model breaks — but so does the therapeutic benefit.
Divergent Claims
Chronic use makes GLP-1s inflationary through 2035
File: GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 Core argument: Lifelong treatment at current pricing creates unsustainable spending growth. The chronic model means costs compound annually. Strongest evidence: Category launch size ($50B+ projected), $2,940/year per patient, CBO/KFF cost modeling.
Low persistence undermines the chronic use assumption
File: glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics Core argument: 85% of non-diabetic obesity patients discontinue by year 2. The chronic model doesn't reflect real-world behavior. Strongest evidence: JMCP study of 125,000+ commercially insured patients; semaglutide 47% one-year persistence vs 19% liraglutide.
What Would Resolve This
- Medicare persistence data: Do Medicare populations (older, sicker, lower OOP after IRA cap) show better persistence than commercial populations?
- Behavioral support impact: Does combining GLP-1s with structured behavioral support (WHO recommendation, BALANCE Model) materially change dropout rates?
- Cost per QALY at real-world persistence: What's the actual cost-effectiveness when modeled with 15% two-year persistence rather than assumed chronic use?
- Generic entry timeline: Do biosimilar/generic GLP-1s at lower price points change the persistence equation by reducing OOP burden?
Cascade Impact
- If chronic costs dominate: Vida's healthcare cost trajectory claims hold. Payer strategy must focus on formulary controls and prior authorization.
- If low persistence dominates: The inflationary projection is overstated. The real problem is wasted therapeutic investment and weight regain cycles. Payer strategy shifts to adherence support.
- If population-dependent: Both are right for different patient segments. The divergence dissolves into scope — diabetic patients may persist while obesity-only patients don't.
Relevant Notes:
- lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence — affordability as persistence driver
- semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x — drug-specific variation
- glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints — multi-organ value complicates pure cost analysis
Topics: